C-11 PET Radiopharmaceuticals: Physics and Use

Carbon-11 is a positron-emitting radionuclide with a physical half-life of only about 20.4 minutes, and that single number dictates almost everything about how a C-11 PET program is built and run. It forces an on-site cyclotron, batch synthesis with meaningful decay during production and quality control, no shipping, and dose-on-demand scheduling — while giving imaging a metabolic tracer that is chemically identical to the body's own molecules.¹²

Where F-18 can be made regionally and shipped as unit doses, C-11 must be produced, tested, and injected in the same building on a tight clock. The tradeoff is worth it because carbon is ubiquitous in biology: labeling a molecule with C-11 leaves its chemistry unchanged, so tracers such as C-11 choline, C-11 acetate, C-11 methionine, and C-11 Pittsburgh Compound-B probe metabolism and receptor biology in ways that are hard to match otherwise.²⁵ This guide walks through the nuclear and positron physics, the 14N(p,α)11C production route and target chemistry, the short-half-life logistics, the main tracers and their uses, quality control under USP and cGMP, the decay-correction math, and the radiation-safety implications a medical physicist and radiation safety officer must plan around.

DRPS supports PET programs through its PET/CT and nuclear medicine physics and radioactive material license support services across Florida, Maryland, Virginia, Washington DC, California, and Nevada. For the closely related fluorine workflow, see our companion article on cyclotron production of fluorine-18.

Introduction

A C-11 PET radiopharmaceutical is a positron-emitting tracer in which a carbon atom in a biologically active molecule has been replaced with carbon-11. Because C-11 and stable C-12 are chemically identical, the labeled molecule behaves exactly like the native compound in the body — a property radiochemists call an isotopic, or "hot-for-cold," substitution.³⁵

The catch is the clock. Carbon-11 decays by half roughly every 20 minutes, so a facility cannot buy C-11 doses the way it buys F-18 FDG from a regional radiopharmacy. Everything — the accelerator, the radiochemistry, the quality-control lab, and the scanner — has to sit within minutes of each other, and the day's schedule has to be built around synthesis batches rather than around a delivery truck.²⁴

This article is organized around that constraint. We start with the decay and positron physics, move through cyclotron production and target chemistry, then examine the logistics, the clinical tracers, quality control, the underlying decay-correction math, and the radiation-protection picture. Throughout, the recurring theme is that with C-11 the half-life is not a detail — it is the design.

Topic Explanation

What carbon-11 is, physically

Carbon-11 has 6 protons and 5 neutrons, making it proton-rich relative to stable carbon. It stabilizes by converting a proton into a neutron, predominantly through positron (β⁺) emission, and decays to stable boron-11.¹ The key numbers a physicist works with are:

• Physical half-life: about 20.4 minutes (approximately 20.36 minutes in current evaluated nuclear data).¹²
• Decay mode: roughly 99.75 percent positron emission, with the small remainder by electron capture.¹
• Positron maximum energy: about 0.96 MeV, with a mean of roughly 0.39 MeV.¹¹⁰
• Annihilation photons: each positron ultimately annihilates with an electron to produce two 511 keV photons emitted nearly back-to-back — the signal every PET scanner detects.¹⁰

Why the positron energy matters for image quality

PET does not localize the decay; it localizes the annihilation. Between emission and annihilation the positron travels a short distance in tissue, and that distance — the positron range — blurs the image. C-11's mean positron range in water is on the order of 1.1 mm, modestly larger than F-18 (about 0.6 mm) but far smaller than high-energy emitters like Ga-68 or Rb-82.¹⁰ In a clinical scanner this range contributes only a small amount of blur, so C-11 images are intrinsically sharp. Our article on PET spatial resolution and positron range works through how these contributions combine in quadrature.

Why an on-site cyclotron is mandatory

The half-life sets a hard logistics limit. After one half-life (20.4 min) half the activity is gone; after an hour, only about an eighth remains. A tracer that must survive synthesis, quality control, and delivery simply cannot tolerate a shipping leg. This is the fundamental difference from F-18, whose ~110-minute half-life supports regional distribution.²⁴ For an overview of how the common positron emitters and therapy isotopes compare, see common PET and radiopharmaceutical-therapy isotopes.

Key Technical Principles

Carbon-11 in the family of short-lived positron emitters

The "organic" PET radionuclides — C-11, N-13, and O-15 — are all cyclotron-made and all short-lived, with F-18 the long-lived outlier that made routine clinical PET practical. The table below places C-11 in context. Positron ranges are representative literature values in water and vary with the tabulation used; they illustrate the ordering rather than exact scanner performance.¹²⁴¹⁰

C-11 sits in the middle: long enough to support real synthetic chemistry and release testing, short enough that shipping is impossible. That is precisely why it is the workhorse of research PET while still requiring the discipline of an on-site accelerator.²⁵

Production via the ¹⁴N(p,α)¹¹C reaction

Almost all clinical and research C-11 is produced by bombarding a nitrogen-14 gas target with protons, driving the ¹⁴N(p,α)¹¹C nuclear reaction, which typically uses proton energies in the range of roughly 7 to 15 MeV.⁴ The chemical form of the C-11 that emerges is controlled by a small additive in the target gas:

• Nitrogen with ~0.1–0.5% oxygen → the C-11 is swept out as [¹¹C]carbon dioxide ([¹¹C]CO₂).
• Nitrogen with ~5% hydrogen → the C-11 emerges as [¹¹C]methane ([¹¹C]CH₄).²⁴

These two gases are the primary building blocks. The great majority of C-11 tracers are then made by converting [¹¹C]CO₂ or [¹¹C]CH₄ into [¹¹C]methyl iodide or [¹¹C]methyl triflate, highly reactive methylating agents that transfer the C-11-labeled methyl group onto a precursor (for example, labeling the nitrogen or oxygen of a target molecule).³ This "C-11 methylation" chemistry is the dominant route because it is fast — and speed is everything when the label is decaying by half every 20 minutes.

The general cyclotron and targetry principles are the same ones covered in our cyclotron F-18 production guide; the neutron field a proton cyclotron generates is addressed in neutron radiation protection for the cyclotron vault.

The decay-correction math

Every quantitative and logistical decision about C-11 flows from the decay law. For an initial activity $A_0$, the activity after elapsed time $t$ is:

$$A(t)=A_0{e}^{-\lambda t},\lambda =\frac{\ln 2}{T_{1/2}}=\frac{0.693}{20.4\text{min}}\approx 0.0340{\text{min}}^{-1}$$

Consider a realistic interval from the end of a synthesis batch through quality control and delivery to the point of injection. Suppose the total elapsed time is 40 minutes (roughly two half-lives):

$$\frac{A(40\text{min})}{A_0}=e^{-0.0340\times 40}=e^{-1.359}\approx 0.257$$

Only about 26 percent of the activity survives that 40-minute delay. To put a 370 MBq (10 mCi) dose in the patient, the synthesis must therefore yield about $370/0.257\approx 1440$ MBq (~39 mCi) at the start of that interval — and any slip in the schedule compounds exponentially. Extend the delay to 60 minutes and the surviving fraction falls to:

$$\frac{A(60\text{min})}{A_0}=e^{-0.0340\times 60}=e^{-2.038}\approx 0.130$$

only about 13 percent. This is the arithmetic behind dose-on-demand scheduling: a C-11 batch cannot be parked, and a late patient can waste an entire synthesis.² Note that for SUV and kinetic-modeling accuracy, all measured activities must additionally be decay-corrected to a common reference time; with C-11 even a few minutes of clock error between the dose calibrator and the scanner produces a meaningful SUV bias.

Batch synthesis, decay during synthesis, and QC

Because the tracer is decaying throughout its own production, C-11 radiochemistry is engineered for minimal steps and maximal speed, almost always on shielded, automated synthesis modules. Decay occurs during the labeling reaction, during purification, and during quality-control testing — so the "yield" that matters clinically is the decay-corrected activity delivered at injection, not the raw activity produced at end of bombardment.²³

Clinical Impact

Carbon-11's clinical and research value comes from labeling endogenous or near-endogenous molecules. The most established tracers are:

C-11 choline — recurrent prostate cancer

C-11 choline targets the upregulated choline metabolism (cell-membrane phospholipid synthesis) of many prostate cancers. The FDA approved Choline C 11 Injection (NDA 203155) on September 12, 2012, for PET imaging of patients with suspected recurrent prostate cancer and non-informative bone scintigraphy, CT, or MRI, to help identify sites of recurrence for subsequent confirmation.⁶ It was the first agent produced and used entirely on site under a full NDA for this indication.

A systematic review and meta-analysis of radiolabeled choline PET/CT in biochemical recurrence found that across 18 studies, roughly 55 percent of patients had a positive scan, with C-11 choline studies using a mean administered activity of about 561 MBq and an uptake time of about 5 minutes — the short uptake being a direct consequence of the half-life.⁷ C-11 choline has since been substantially superseded in many centers by PSMA-targeted agents, but it remains a validated, FDA-approved option and a clear illustration of on-site C-11 imaging. See our related coverage of F-18 fluciclovine for prostate cancer and Ga-68 PSMA PET.

C-11 acetate — oxidative metabolism and tumors

C-11 acetate traces oxidative metabolism: it is taken up and incorporated into the tricarboxylic-acid cycle, making it useful for imaging myocardial oxygen consumption and for certain tumors (including well-differentiated hepatocellular carcinoma and prostate cancer), where it can complement or outperform FDG in low-glycolytic disease.⁵ As a metabolic substrate labeled at a native carbon position, it is a textbook example of the endogenous-tracer advantage of C-11.⁵

C-11 methionine — brain tumors

C-11 methionine (MET) is the most widely used amino-acid PET tracer for brain tumors. Because normal brain cortex shows low amino-acid uptake, MET gives high tumor-to-background contrast and good lesion delineation. A comprehensive review documented its roles in glioma diagnosis, grading, biopsy and radiotherapy target planning, and — importantly — distinguishing tumor recurrence from radiation necrosis, a question FDG often cannot answer.⁸ Its short half-life confines MET imaging to centers with an on-site cyclotron.

C-11 PiB — amyloid research

C-11 Pittsburgh Compound-B (PiB) is the tracer that launched in-vivo amyloid imaging. The first human study, published in 2004, showed marked cortical retention of PiB in patients with Alzheimer disease versus controls and demonstrated that PET could quantify amyloid deposits in living subjects.⁹ PiB remains a research reference standard, though clinical amyloid imaging has largely shifted to F-18-labeled agents precisely because they can be distributed without an on-site cyclotron. Our article on amyloid and tau brain PET covers that clinical landscape.

The through-line is consistent: C-11 tracers deliver biologically faithful, high-contrast imaging, but the half-life restricts them to cyclotron-equipped academic and specialized centers.²⁵

Practical Optimization Tips

Running a C-11 program well is largely an exercise in beating the clock without cutting corners. Practical priorities include:

Design the schedule around synthesis, not the scanner

• Couple production to the imaging slot. Build the daily schedule so each synthesis lands minutes before the patient is ready to inject. A parked batch is wasted activity.
• Plan yields with the decay factor built in. Back-calculate the required end-of-synthesis activity from the desired injected dose and the realistic elapsed time, as in the worked example above. Leave margin for a short QC delay.
• Have a contingency for a late patient. Because C-11 cannot wait, decide in advance whether to re-synthesize or reschedule; do not improvise with a decayed dose.

Engineer the chemistry and QC for speed

• Automate and shield the synthesis. Use validated automated modules to minimize both handling dose and elapsed time.
• Favor late-stage labeling. Introduce the C-11 as late in the synthesis as possible (the methylation step), so decay during earlier chemistry is avoided.³
• Pre-stage quality control. Have TLC/HPLC systems, the dose calibrator, and endotoxin testing warmed up and ready so release testing starts the instant the batch is available. See radiochemical purity by TLC and dose calibrator QC.

Protect quantification

• Synchronize clocks. Ensure the dose calibrator, injection log, and scanner clock agree; with a 20.4-minute half-life, a 2-minute discrepancy is a ~7 percent activity error that propagates directly into SUV.
• Verify the radionuclide identity by half-life. A half-life measurement (and 511 keV energy check) is both a QC requirement and a guard against contamination by longer-lived impurities.¹
• Standardize uptake and acquisition timing. Fixed, short uptake intervals keep dynamic and static quantification comparable across patients.

Handle the source safely and briefly

• Use 511 keV-appropriate shielding. Tungsten syringe shields, L-blocks, and vial pigs sized for annihilation photons, plus distance and speed, control staff dose.
• Let waste decay. C-11 waste reaches background in a few hours, simplifying disposal relative to longer-lived isotopes.

Regulatory Considerations

A C-11 PET program sits at the intersection of FDA drug regulation and NRC or Agreement State radioactive-material regulation, and both frameworks apply simultaneously. The C-11 tracer is a drug that also happens to be radioactive byproduct material.

• FDA cGMP for PET drugs — 21 CFR Part 212. PET drugs produced for routine clinical use must be manufactured under current good manufacturing practice specific to PET, which governs facilities, equipment, components, production and process controls, laboratory controls, and release.¹¹ An approved product such as Choline C 11 Injection is produced under its NDA and cGMP.⁶¹¹
• USP General Chapter <823>. This chapter, Positron Emission Tomography Drugs for Compounding, Investigational, and Research Uses, provides quality-assurance standards for PET drugs produced for compounding, investigational, or research purposes — the framework under which many non-approved C-11 tracers (acetate, methionine, PiB) are made and used.¹² Confirm the current official version, as USP chapters are periodically revised.
• USP General Chapter <825>. This chapter governs the preparation, compounding, dispensing, and repackaging of radiopharmaceuticals in state-licensed settings (facilities, engineering controls, personnel training, and procedural standards) downstream of production.¹³ See our overview of USP <825> radiopharmaceutical compounding.
• Radioactive-material licensing — NRC 10 CFR Parts 20 and 35. Possession and medical use of C-11 fall under 10 CFR Part 20 (standards for protection against radiation) and 10 CFR Part 35 (medical use of byproduct material), or the equivalent Agreement State program.

Agreement State jurisdiction matters. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC is regulated directly by the NRC. A facility must confirm which authority issues its license and which release-testing, survey, and reporting requirements apply. Release testing for a C-11 drug typically includes appearance, pH, radiochemical and chemical purity, radionuclidic identity (half-life and 511 keV energy), residual solvents, radioactivity concentration, filter integrity, and bacterial endotoxin testing; because of the half-life, some tests are completed after a validated conditional release.¹¹¹²

Frequently Asked Questions (FAQs)

What is the half-life of carbon-11 and why does it matter?

Carbon-11 has a physical half-life of about 20.4 minutes. This is long enough to synthesize a tracer, run release testing, and image a patient close to the production site, but far too short for shipping. The half-life is the single design constraint that forces C-11 programs to have an on-site cyclotron and to schedule doses on demand.

How is carbon-11 produced?

Almost all clinical carbon-11 is made on a medical cyclotron by bombarding nitrogen-14 gas with protons, driving the 14N(p,α)11C nuclear reaction. A small amount of oxygen (about 0.1 to 0.5 percent) in the target produces [11C]carbon dioxide, while a small amount of hydrogen (about 5 percent) produces [11C]methane. These primary building blocks feed the labeling chemistry.

Why does a C-11 program need its own cyclotron when many F-18 centers do not?

F-18 has a roughly 110-minute half-life, so unit doses can be shipped from a regional radiopharmacy. C-11 decays by half every 20.4 minutes, so after a typical shipping delay almost nothing usable remains. Practical C-11 use therefore requires a cyclotron and radiochemistry in the same building as the PET scanner.

Is C-11 choline FDA approved?

Yes. The FDA approved Choline C 11 Injection (NDA 203155) on September 12, 2012, for PET imaging of patients with suspected recurrent prostate cancer and non-informative bone scintigraphy, CT, or MRI. Because of the short half-life, it is produced and used at the same site.

What are the main carbon-11 PET tracers?

The most established are C-11 choline for recurrent prostate cancer, C-11 acetate for oxidative metabolism and some tumors, C-11 methionine for brain tumors, and C-11 Pittsburgh Compound-B (PiB) for amyloid research. Most C-11 tracers other than approved C-11 choline are used under an investigational or research framework.

What quality control is required before releasing a C-11 PET drug?

C-11 release testing typically includes appearance, pH, radiochemical and chemical purity, radionuclidic identity (half-life and 511 keV photon energy), residual solvents, radioactivity concentration, filter integrity, and bacterial endotoxin testing, performed under FDA 21 CFR Part 212 or the applicable USP framework. Because of the half-life, some tests are completed after conditional release under a validated process.

What are the radiation-safety implications of a rapid-decay positron emitter like C-11?

Handling involves 511 keV annihilation photons, which are highly penetrating, so tungsten or lead syringe and vial shields, remote handling, and short handling times matter. The upside is that spills and waste decay to background very quickly, and patient and staff dose is limited by the short half-life. Programs still work under 10 CFR Parts 20 and 35 or the equivalent Agreement State rules.

Key Takeaways

• The 20.4-minute half-life is the design. It mandates an on-site cyclotron, batch synthesis, no shipping, and dose-on-demand scheduling.¹²
• C-11 is a near-ideal positron emitter for image quality. About 99.75 percent β⁺ decay, a 0.96 MeV maximum positron energy, and a ~1.1 mm mean positron range give sharp, quantitatively useful images.¹¹⁰
• Production is the ¹⁴N(p,α)¹¹C reaction. Target additives set the chemical form — [¹¹C]CO₂ (with trace O₂) or [¹¹C]CH₄ (with trace H₂) — which feed rapid [¹¹C]methyl iodide/triflate methylation chemistry.²³⁴
• The tracers are biologically faithful. C-11 choline (FDA-approved, recurrent prostate cancer), C-11 acetate (oxidative metabolism), C-11 methionine (brain tumors), and C-11 PiB (amyloid research) exploit isotopic labeling of native molecules.⁵⁶⁷⁸⁹
• Decay correction is unforgiving. Clock synchronization and back-calculated yields are essential; a few minutes of error is a several-percent activity and SUV error.
• Two regulatory frameworks apply at once. FDA 21 CFR Part 212 or USP <823>/<825> for the drug, and NRC 10 CFR Parts 20/35 (or Agreement State rules) for the material.¹¹¹²¹³

Conclusion

Carbon-11 is the radionuclide that best rewards physics discipline. Its short half-life is simultaneously its greatest limitation — no shipping, an obligatory on-site cyclotron, relentless scheduling pressure — and part of its appeal, because it enables faithful metabolic imaging with low patient dose and fast-decaying waste. A successful C-11 program couples the cyclotron, the radiochemistry lab, the QC bench, and the scanner into a single tightly timed workflow, and it treats decay correction and clock synchronization as first-class quality issues rather than afterthoughts.

For a medical physicist and radiation safety officer, the mandate is clear: engineer for speed and shielding, validate synthesis and release testing to the applicable FDA or USP standard, keep licensing current with the authority having jurisdiction, and build the schedule so the arithmetic of exponential decay works for the program rather than against it.

How DRPS Can Help

Diagnostic Radiation Physics Services (DRPS) supports PET and cyclotron-based programs with PET/CT and nuclear medicine physics, dose-calibrator and instrument QC, shielding and radiation-safety program support, and radioactive material license support prepared by board-certified medical physicists. We help facilities align production, quality control, safety, and licensing across the FDA, USP, and NRC or Agreement State frameworks, and we provide medical physicist consulting for programs adding short-lived positron emitters.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong PET program is not just about passing inspection. It is about making the fast, safe, compliant process the routine one for the clinical and radiochemistry teams.

Related Resources

• Cyclotron production of fluorine-18
• Common PET & radiopharmaceutical-therapy isotopes
• PET spatial resolution and positron range
• N-13 ammonia cardiac PET perfusion
• Radiopharmacy aseptic technique and QC
• USP <825> radiopharmaceutical compounding
• PET/CT and nuclear medicine physics
• Radioactive material license support

References

1. National Nuclear Data Center, Brookhaven National Laboratory. NuDat: Nuclear structure and decay data for carbon-11. nndc.bnl.gov
2. Pees A, Chassé M, Lindberg A, Vasdev N. Recent developments in carbon-11 chemistry and applications for first-in-human PET studies. Molecules. 2023;28(3):931. doi:10.3390/molecules28030931. PubMed
3. Tu Z, Mach RH. C-11 radiochemistry in cancer imaging applications. Curr Top Med Chem. 2010;10(11):1060-1095. doi:10.2174/156802610791384261. PubMed
4. International Atomic Energy Agency. Nuclear Data Services — Medical Portal: ¹⁴N(p,α)¹¹C recommended cross sections for carbon-11 production. iaea.org
5. Neumann KD, Flavell RR, Wilson DM. Exploring metabolism in vivo using endogenous ¹¹C metabolic tracers. Semin Nucl Med. 2017;47(5):461-473. doi:10.1053/j.semnuclmed.2017.05.003. PubMed
6. U.S. Food and Drug Administration. Choline C 11 Injection — approval letter and prescribing information (NDA 203155; approved September 12, 2012). accessdata.fda.gov
7. von Eyben FE, Kairemo K. Acquisition with ¹¹C-choline and ¹⁸F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Ann Nucl Med. 2016;30(6):385-392. doi:10.1007/s12149-016-1078-7. PubMed
8. Glaudemans AWJM, Enting RH, Heesters MAAM, et al. Value of ¹¹C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40(4):615-635. doi:10.1007/s00259-012-2295-5. PubMed
9. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. doi:10.1002/ana.20009. PubMed
10. Levin CS, Hoffman EJ. Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution. Phys Med Biol. 1999;44(3):781-799. doi:10.1088/0031-9155/44/3/019. PubMed
11. U.S. Food and Drug Administration. 21 CFR Part 212: Current Good Manufacturing Practice for Positron Emission Tomography Drugs. ecfr.gov
12. United States Pharmacopeia. General Chapter <823> Positron Emission Tomography Drugs for Compounding, Investigational, and Research Uses. usp.org
13. United States Pharmacopeia. General Chapter <825> Radiopharmaceuticals—Preparation, Compounding, Dispensing, and Repackaging. usp.org